IPSEN SA SP.ADR 1/4/ EO 1 - Asset Resilience Ratio
IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) has an Asset Resilience Ratio of 0.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how IPSEN SA SP.ADR 1/4/ EO 1's Asset Resilience Ratio has changed over time. See IPSEN SA SP.ADR 1/4/ EO 1 leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down IPSEN SA SP.ADR 1/4/ EO 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is IPSEN SA SP.ADR 1/4/ EO 1 worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.00 Million | 0.01% |
| Total Liquid Assets | €1.00 Million | 0.01% |
Asset Resilience Insights
- Limited Liquidity: IPSEN SA SP.ADR 1/4/ EO 1 maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
IPSEN SA SP.ADR 1/4/ EO 1 Industry Peers by Asset Resilience Ratio
Compare IPSEN SA SP.ADR 1/4/ EO 1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401 |
Drug Manufacturers - Specialty & Generic | 5.09% |
|
KPC Pharmaceuticals Inc
SHG:600422 |
Drug Manufacturers - Specialty & Generic | 16.37% |
Annual Asset Resilience Ratio for IPSEN SA SP.ADR 1/4/ EO 1 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for IPSEN SA SP.ADR 1/4/ EO 1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | €1.00 Million ≈ $1.17 Million |
€6.94 Billion ≈ $8.11 Billion |
0.00pp |
| 2024-12-31 | 0.02% | €1.10 Million ≈ $1.29 Million |
€6.44 Billion ≈ $7.53 Billion |
-0.15pp |
| 2023-12-31 | 0.17% | €10.60 Million ≈ $12.39 Million |
€6.32 Billion ≈ $7.39 Billion |
-0.38pp |
| 2022-12-31 | 0.55% | €31.00 Million ≈ $36.24 Million |
€5.61 Billion ≈ $6.56 Billion |
-0.30pp |
| 2021-12-31 | 0.85% | €42.40 Million ≈ $49.57 Million |
€4.99 Billion ≈ $5.83 Billion |
-- |
About IPSEN SA SP.ADR 1/4/ EO 1
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more